The company has a presence across six states and 13 cities in India. As of December 31, 2025, it operated 15 diagnostic centres across Uttar Pradesh, Andhra Pradesh, Karnataka, West Bengal, Haryana/NCR Delhi and Kerala, although operations in Kerala had not commenced.
The company operates through four different service models. As of December 31, 2025, it had seven centres under public-private partnerships, three under private-private partnerships, three through strategic partnerships with government PSUs and two standalone private centres along with a processing unit.
The company claims to have a diversified diagnostic equipment base. As of December 31, 2025, its operations were supported by seven CT machines, seven MRI machines, 20 X-ray machines, two Dexa scan machines, two mammography machines, 15 ultrasound machines, one PET-CT, six CR systems and three DR systems.
The company provides services to B2G, B2B and B2C customers. For the nine months ended December 31, 2025, government-related business contributed 61.32% of revenue from operations, while B2B and B2C customers contributed 20.09% and 18.60%, respectively.
The company claims to have technology-enabled diagnostic capabilities across radiology and pathology. Its radiology services use MRI, CT, X-ray, ultrasound, Dexa scan and mammography equipment, while its pathology operations use fully automatic analysers for basic and specialised tests.
The company has witnessed a consistent increase in its revenue from operations and profit after tax (PAT). Revenue from operations increased from Rs 30.58 crore in FY23 to Rs 35.23 crore in FY24 and Rs 38.24 crore in FY25. PAT increased from Rs 5.87 crore in FY23 to Rs 7.62 crore in FY24 and Rs 11.54 crore in FY25.
The company derives a significant portion of its revenue from Public Private Partnership (PPP) arrangements with government authorities. PPP arrangements contributed Rs 27.10 crore (70.88%), Rs 27.20 crore (77.22%), and Rs 22.73 crore (74.33%) to revenue from operations for the period FY25, FY24, and FY23, respectively. Any non-renewal, modification, or termination of these MoUs, deterioration in relationships with public hospitals, or delays or failures in receiving payments could adversely affect the company’s business, financial condition, and results of operations.
The company is heavily dependent on its radiology services, which contributed Rs 36.77 crore (96.17%), Rs 33.76 crore (95.82%), and Rs 29.09 crore (95.13%) to revenue from operations for the period FY25, FY24, and FY23, respectively. Any disruption to radiology services, increased equipment and maintenance costs, or failure to comply with regulations relating to patient safety, radiation exposure and data privacy could adversely affect the company’s business, financial condition and results of operations.
The company derives a substantial portion of its revenue from Andhra Pradesh, which contributed Rs 33.54 crore (87.71%), Rs 30.53 crore (86.66%), and Rs 27.57 crore (90.16%) to revenue from operations for the period FY25, FY24, and FY23, respectively. Any regional slowdown in economic activity, political or civil unrest, disruption, or sustained economic downturn in Andhra Pradesh could reduce demand for the company’s services and adversely affect its business, financial condition and results of operations.
The company is dependent on a limited number of key customers cum patients for a substantial portion of its revenue. Its top 10 customers cum patients contributed Rs 29.27 crore (76.55%), Rs 28.81 crore (81.78%), and Rs 23.47 crore (76.76%) to revenue from operations for the period FY25, FY24, and FY23, respectively. Any loss of these key customers cum patients, reduction in their business with the company, or inability to replace them could adversely affect its revenue, profitability, cash flows and results of operations.
The company derives a significant portion of its revenue from government authorities through its B2G business. B2G revenue contributed Rs 27.10 crore (70.88%), Rs 27.20 crore (77.22%), and Rs 22.73 crore (74.33%) to revenue from operations for FY25, FY24, and FY23, respectively. But any loss of relationships with government authorities, changes in government policies, or delays in payments could adversely affect the company’s business, financial condition, and results of operations.
The company has certain outstanding civil, criminal, tax, statutory, and regulatory proceedings against it. Any adverse outcome in these matters could hurt the company’s business, reputation, financial condition, and results of operations.
The company has recorded negative cash flows from investing activities amounting to Rs 29.67 crore, Rs 10.65 crore, Rs 1.38 crore, and Rs 3.74 crore for the period ended December 31, 2025, FY25, FY24, and FY23, respectively, primarily due to the purchase of fixed assets and capital work-in-progress, as well as changes in non-current investments. It also recorded negative cash flows from financing activities amounting to Rs 0.52 crore, Rs 6.39 crore, Rs 10.81 crore, and Rs 1.13 crore during the same periods, mainly due to repayments of long-term and short-term borrowings and finance costs. Whether these investments result in increased topline and bottomline will remain key monitorables for investors.
As of December 31, 2025, the company had outstanding total borrowings of Rs 11.03 crore, with secured borrowings accounting for the full amount. Any failure to service or repay these borrowings could adversely affect the company’s business, financial condition, and results of operations.